Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963141 | 0.92 | PARP1 (0.61) | PARP1HTR2BPKMPOLBKDM4E | |
| SCHEMBL665072 | 0.92 | PARP1 (0.58) | PARP1HTR2BPKMPARP2KMT2A | |
| SCHEMBL18781846 | 0.89 | HTR2B (0.52) | PARP1HTR2BPKMPOLBKDM4E | |
| SCHEMBL9869744 | 0.82 | PKM (0.56) | PARP1HTR2BPKMPOLBKDM4E | |
| SCHEMBL30365989 | 0.82 | PKM (0.56) | PARP1HTR2BPKMPOLBKDM4E | |
| SCHEMBL664921 | 0.82 | HTR2B (0.57) | HTR2BPKMPOLBKDM4EKMT2A | |
| SCHEMBL9869376 | 0.80 | HTR2B (0.60) | HTR2BPKMPOLBKDM4EKMT2A | |
| SCHEMBL14833923 | 0.79 | POLB (0.40) | PARP1HTR2BPKMPOLB | |
| SCHEMBL6883705 | 0.79 | PKM (0.62) | PARP1HTR2BPKMKMT2A | |
| SCHEMBL666433 | 0.77 | PARP1 (0.60) | PARP1HTR2BPKMPARP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-5063228-A | 4-(substitutedaminoethyl)-3,4-dihydro-2-alkylpyrimido[1,6-a]benzimidazol-1(2H)-ones as antiarrhythmic agents | A. H. ROBBINS COMPANY, INCORPORATED (US) | 1991-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885HTR2B 1566/4885PKM 450/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885HTR2B 1566/4885PKM 450/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885HTR2B 1566/4885PKM 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.